title: A phase II study of cisplatin /S-1 in patients with carcinomas of unknown primary site.
abstract: BACKGROUND
  Carcinomas of unknown primary site (CUPs) are heterogeneous tumors associated with a poor prognosis. This phase II trial was designed to evaluate the efficacy and safety of a novel combination chemotherapy of S-1 and cisplatin (CDDP) in patients with CUP.
  
  
  METHODS
  Patients with previously untreated CUPs were eligible for this trial. The treatment schedule consisted of oral S-1 (40 mg/m(2)) twice a day on days 1-21, and intravenous CDDP (60 mg/m(2)) on day 8. This schedule was repeated every 5 weeks.
  
  
  RESULTS
  A total of 46 patients were enrolled. The overall response rate and the disease control rate were 41.3% and 80.4%, respectively. The median overall survival time was 17.4 months. Grade 3/4 neutropenia, thrombocytopenia, and febrile neutropenia occurred in 28.3%, 13.0%, and 2.2% of the patients, respectively.
  
  
  CONCLUSIONS
  CDDP plus S-1 combination chemotherapy is well tolerated and active first-line empiric therapies for patients with CUP.
authors: Division of thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo Nagaizumi-cho, Sunto-gun, Shizuoka, 411-8777, Japan, a-tsuya@hospital.city.osaka.jp.
authors: Asuka
authors: A
authors: Tsuya
authors: Takayasu
authors: T
authors: Kurata
authors: Akihiro
authors: A
authors: Tamiya
authors: Isamu
authors: I
authors: Okamoto
authors: Shinya
authors: S
authors: Ueda
authors: Daisuke
authors: D
authors: Sakai
authors: Naotoshi
authors: N
authors: Sugimoto
authors: Koji
authors: K
authors: Matsumoto
authors: Isao
authors: I
authors: Goto
authors: Nobuyuki
authors: N
authors: Yamamoto
authors: Masahiro
authors: M
authors: Fukuoka
authors: Kazuhiko
authors: K
authors: Nakagawa
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage* / Q000009:adverse effects; D002277:Carcinoma / Q000188:drug therapy* / Q000556:secondary; D002945:Cisplatin / Q000008:administration & dosage* / Q000009:adverse effects; D004338:Drug Combinations; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009382:Neoplasms, Unknown Primary / Q000188:drug therapy*; D010094:Oxonic Acid / Q000008:administration & dosage* / Q000009:adverse effects; D005641:Tegafur / Q000008:administration & dosage* / Q000009:adverse effects; D016896:Treatment Outcome
chemical_list: D000964:Antimetabolites, Antineoplastic; D004338:Drug Combinations; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid; D002945:Cisplatin
references: Breast Cancer. 2004;11(2):194-202
references: 15550867
references: Br J Cancer. 2000 Jul;83(2):141-5
references: 10901361
references: Ann Oncol. 2000 Feb;11(2):211-5
references: 10761758
references: J Clin Oncol. 2002 Mar 15;20(6):1651-6
references: 11896116
references: Clin Cancer Res. 2004 Dec 1;10(23):7860-4
references: 15585618
references: Proc Natl Acad Sci U S A. 1986 Dec;83(23):8923-5
references: 3466165
references: J Clin Oncol. 2010 Mar 20;28(9):1547-53
references: 20159816
references: Anticancer Drugs. 1996 Jul;7(5):548-57
references: 8862723
references: Cancer J. 2010 Jan-Feb;16(1):70-5
references: 20164695
references: J Clin Oncol. 2005 Oct 1;23(28):6957-65
references: 16145066
references: J Clin Oncol. 2007 May 1;25(13):1747-52
references: 17470864
references: J Clin Oncol. 2008 Sep 20;26(27):4442-8
references: 18802157
references: Br J Cancer. 2001 Sep 28;85(7):939-43
references: 11592762
references: Eur J Cancer. 1998 Oct;34(11):1715-20
references: 9893658
references: Oncologist. 2004;9(6):644-52
references: 15561808
references: N Engl J Med. 1993 Jul 22;329(4):257-63
references: 8316270
references: J Clin Oncol. 2000 Sep;18(17):3101-7
references: 10963638
references: J Natl Cancer Inst. 2000 Feb 2;92(3):205-16
references: 10655437
references: Lancet Oncol. 2008 Mar;9(3):215-21
references: 18282805
references: Semin Oncol. 2009 Feb;36(1):38-43
references: 19179186
references: J Clin Oncol. 2003 Sep 15;21(18):3479-82
references: 12972523
references: J Clin Oncol. 1997 Jun;15(6):2385-93
references: 9196154
references: Semin Oncol. 1993 Jun;20(3):261-7
references: 7684858